# Molecular Partners AG (MOLN)

Source: https://www.quantisnow.com/company/MOLN
Generated: 2026-11-13T06:53:46.850Z

- Ticker: MOLN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001745114
- Website: https://www.molecularpartners.com

## About

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

## Latest MOLN news and filings

- 2026-11-13 06:00 UTC [Conference Announcement] [Molecular Partners to Present at Inaugural UBS Global Biopharma Conference](https://www.quantisnow.com/insight/molecular-partners-to-present-at-inaugural-ubs-global-biopharma-conference-6789142)
- 2026-11-06 06:00 UTC [Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026](https://www.quantisnow.com/insight/molecular-partners-presents-new-preclinical-data-for-next-generation-t-cell-6777649)
- 2026-11-05 06:00 UTC [Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026](https://www.quantisnow.com/insight/molecular-partners-to-present-on-dll3-targeting-radio-darpin-mp0712-at-2026-6773916)
- 2026-10-29 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6762121)
- 2026-10-29 06:00 UTC [Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy](https://www.quantisnow.com/insight/molecular-partners-reports-q3-2026-financial-results-deepens-focus-on-6761971)
- 2026-10-22 05:00 UTC [Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70](https://www.quantisnow.com/insight/molecular-partners-nominates-mp0730-as-next-candidate-in-expanding-pipeline-6754014)
- 2026-08-25 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6693456)
- 2026-08-25 05:00 UTC [Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study](https://www.quantisnow.com/insight/molecular-partners-reports-h1-2026-financial-results-and-corporate-highlights-6693381)
- 2026-07-20 12:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6641991)
- 2026-07-16 05:00 UTC [Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma](https://www.quantisnow.com/insight/molecular-partners-announces-clinical-progress-in-phase-2-tactic-combination-6638757)
- 2026-07-06 05:00 UTC [Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics](https://www.quantisnow.com/insight/molecular-partners-updates-on-clinical-progress-across-expanding-pipeline-of-6627044)
- 2026-07-02 10:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6624046)
- 2026-07-02 05:00 UTC [Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712](https://www.quantisnow.com/insight/molecular-partners-and-orano-med-announce-first-patients-dosed-in-6623969)
- 2026-06-24 20:07 UTC [SEC Form S-8] [SEC Form S-8 filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-molecular-partners-ag-6614169)
- 2026-06-01 11:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6580569)
- 2026-05-30 12:00 UTC [Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1](https://www.quantisnow.com/insight/molecular-partners-holds-presentations-at-asco-and-snmmi-2026-on-6580213)
- 2026-05-26 20:00 UTC [Conference Announcement] [Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit](https://www.quantisnow.com/insight/molecular-partners-to-present-at-td-cowens-7th-annual-oncology-6571952)
- 2026-05-12 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6547770)
- 2026-05-12 20:00 UTC [Earnings] [Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317](https://www.quantisnow.com/insight/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-6547714)
- 2026-05-04 05:00 UTC [Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences](https://www.quantisnow.com/insight/molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-candidate-6527731)
- 2026-05-01 13:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6526136)
- 2026-05-01 11:00 UTC [Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling](https://www.quantisnow.com/insight/molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-6525855)
- 2026-04-19 16:00 UTC [Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712](https://www.quantisnow.com/insight/molecular-partners-presents-three-posters-at-aacr-2026-with-new-6505682)
- 2026-04-14 20:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6499812)
- 2026-04-14 20:00 UTC [Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting](https://www.quantisnow.com/insight/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-6499392)
- 2026-03-30 11:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6475786)
- 2026-03-23 13:00 UTC [Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors](https://www.quantisnow.com/insight/molecular-partners-publishes-invitation-to-annual-general-meeting-2026-and-6464514)
- 2026-03-19 06:00 UTC [Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes](https://www.quantisnow.com/insight/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amenability-to-6460323)
- 2026-03-17 20:30 UTC [Molecular Partners to Hold Three Poster Presentations at AACR 2026](https://www.quantisnow.com/insight/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026-6452786)
- 2026-03-13 17:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6446597)
- 2026-03-12 20:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6445169)
- 2026-03-12 20:34 UTC [SEC Form 20-F filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-molecular-partners-ag-6444981)
- 2026-03-12 20:00 UTC [Molecular Partners Reports Highlights and Financial Results for Full Year 2025](https://www.quantisnow.com/insight/molecular-partners-reports-highlights-and-financial-results-for-full-year-6444208)
- 2026-02-26 06:00 UTC [Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results](https://www.quantisnow.com/insight/molecular-partners-announces-participation-in-march-investor-conferences-and-upcoming-6414447)
- 2026-02-26 06:00 UTC [Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics](https://www.quantisnow.com/insight/molecular-partners-signs-development-agreement-with-eckert-ziegler-for-targeted-6414446)
- 2026-02-02 11:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6368843)
- 2026-02-02 06:00 UTC [Earnings Date] [Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026](https://www.quantisnow.com/insight/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-6368651)
- 2026-01-27 13:47 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-molecular-partners-ag-with-a-6361729)
- 2026-01-12 22:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Molecular Partners AG](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-molecular-partners-ag-6346763)
- 2026-01-11 20:00 UTC [Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference](https://www.quantisnow.com/insight/molecular-partners-highlights-clinical-development-progress-and-anticipated-milestones-at-6345062)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MOLN
- Earnings history: https://www.quantisnow.com/earnings/MOLN
- Dividend history: https://www.quantisnow.com/dividends/MOLN
- Insider transactions: https://www.quantisnow.com/insiders/MOLN
- Options chain: https://www.quantisnow.com/options/MOLN
- SEC 8-K filings only: https://www.quantisnow.com/company/MOLN/8-k
- RSS and alerts for MOLN: https://www.quantisnow.com/docs/rss-feeds.md